Basilea buys Spexis’ preclinical antibiotics programme for $2.3m

2024-01-15

交易

并购引进/卖出

Basilea buys Spexis’ preclinical antibiotics programme for $2.3m

Preview

来源: Pharmaceutical Technology

Switzerland-based Basilea Pharmaceutica has entered into an asset purchase agreement with Spexis to acquire the latter’s preclinical program of antibiotics in a deal worth SFr2m ($2.3m).

Basilea will pay up to SFr2m in upfront, asset transfer and milestone-based payments. Furthermore, Basilea will also assume licencing rights and obligations from Spexis, royalties on sales which were promised under licensing agreements, as per a 15 January press release.

Following the news, the stock for Switzerland based Spexis went up by over 16.7% during trading on 15 January.

Spexis’ antibiotic programme was developed using its outer membrane protein targeting antibiotics (OMPTA) technology that selectively disrupts the lipopolysaccharide transport bridge. The new OMPTA class of antibiotics binds dually to lipopolysaccharide and outer-membrane proteins. These proteins are responsible for providing structural integrity and a permeability barrier to protect the gram-negative bacterial cell. Its disruption can cause the bacteria to die.

Spexis’ OMPTA class molecule POL7306 is currently in pre-clinical development. The Spexis’ antibiotic programme was funded in part by Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership established to accelerate antibacterial products to address drug-resistant bacteria.

Basilea’s pipeline consists of multiple antifungals and antibiotics. The company is seeking approval from the US Food and Drug Administration (FDA) for its antibiotic ceftobiprole. The Prescription Drug User Fee Act (PDUFA) goal date for the new drug application (NDA) for ceftobiprole is set for 3 April 2024. Concurrently, the company is also seeking a partner to commercialise the drug in the US.

Antimicrobial resistance (AMR) has been a growing issue in recent years, with the World Health Organisation (WHO) declaring it one of the top global public health and development threats. In August 2023, the UK pledged up to £210m ($267.7m) to help track antibiotic-resistant bacteria across Asia and Africa. The investment aimed to identify dangerous superbugs before they arrived in the country.

In recent months, multiple companies have invested in developing antibiotic therapies. In September 2023, Novo Holding acquired Boston-based Paratek Pharmaceuticals to bolster its AMR expertise. Paratek’s portfolio consisted of Nuzyra (omadacycline), a marketed once-a-day oral and intravenous antibiotic indicated for CABP and ABSSSI.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

Basilea Medical Ltd.